Evaxion A (EVAX) Non-Current Deferred Tax Liability (2022 - 2025)
Evaxion A's (EVAX) quarterly Non-Current Deferred Tax Liability came in at $156000.0 in Q4 2025, up 19.08% YoY from $131000.0 in Q4 2024, and up 19.08% on a QoQ basis from $131000.0 in Q4 2024.
Evaxion A (EVAX) Non-Current Deferred Tax Liability (2022 - 2025) Analysis & Trends
Evaxion A (EVAX) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $156000.0 in Q4 2025.
- Quarterly Non-Current Deferred Tax Liability rose 19.08% year-over-year to $156000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $156000.0 (up 19.08% YoY) and the FY2025 annual result came in at $156000.0, up 19.08% from the prior year.
- Non-Current Deferred Tax Liability climbed to $156000.0 in Q4 2025, from $131000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $214000.0 in Q4 2022 to a low of $126000.0 in Q4 2023.
- A 4-year average of $156750.0 and a median of $143500.0 in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability slumped 41.12% — and 2025, when it climbed 19.08%.
- Tracing EVAX's Non-Current Deferred Tax Liability over 4 years: stood at $214000.0 in 2022, then slumped by 41.12% to $126000.0 in 2023, then advanced by 3.97% to $131000.0 in 2024, then rose by 19.08% to $156000.0 in 2025.
- The last three Non-Current Deferred Tax Liability figures came in at $156000.0 (Q4 2025), $131000.0 (Q4 2024), and $126000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 156,000.00 |
| Dec 31, 2025 | 156,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Dec 31, 2023 | 126,000.00 |
| Dec 31, 2023 | 126,000.00 |
| Dec 31, 2022 | 214,000.00 |
| Dec 31, 2022 | 214,000.00 |